Autonomous microfluidic electrochemical nano-biosensors for highly sensitive and selective detection and monitoring of biomarkers

目前为快速检测生物流体标志物而开发的护理点分析和设备正在应对自动化、多路传输、定量测量、重复性、可伸缩性或成本方面的至少一个挑战。该项目旨在开发一种新的可扩展和可重现的毛细管微流控电化学纳米生物传感(CAMEN)平台，使复杂的定量生物分析完全自动化，从而实现低成本和护理点生物标志物的检测。 目标1：开发可重复性和超灵敏的电化学纳米生物传感器；目标2：开发毛细管微流控组件和Camen平台；目标3：利用Camen平台检测添加/临床样品中的生物标记物。 在两年结束时，我们将展示导电纳米材料/油墨的新型组合物的生产及其在柔性衬底上的丝网印刷，使电极能够一步转化为电化学纳米生物传感器。该项目还将导致开发一种新的微流控平台，该平台具有已开发的特化毛细管微流控组件库，一旦结合起来，可以将复杂的电化学生物传感方案自动化到一个芯片中。我们建议的卡门生物检测将1)自动化和定量的样本到结果测试，2)模块化，易于适应进行新的检测，3)具有在单个试剂盒中同时检测各种类型的生物标志物的多路复用能力，4)快速(&lt；20分钟)和低成本(&lt；15-20美元)，以及5)由于无线信号传输到Web-App和云系统，与数字健康监测兼容，与加拿大新兴数字健康平台的需求保持一致。该项目将为加拿大创造对微纳技术、诊断平台和医疗器械相关产品和知识产权的需求，从而为加拿大带来经济效益。

The present point-of-care assays and devices developed for rapid detection of biofluid markers are dealing with at least one of the challenges of automation, multiplexing, quantitative measurement, reproducibility, scalability, or cost. This project aims to develop a new scalable and reproducible CApillary Microfluidic Electrochemical Nano-biosensing (CAMEN) platform which enables full automation of complex quantitative bioassays for low-cost and point-of-care detection of biomarkers. Objective #1: Development of reproducible and ultrasensitive electrochemical nano-biosensors; Objective #2: Development of capillary microfluidic components and the CAMEN platform; Objective #3: Employment of the CAMEN platform for detecting biomarkers in spiked/clinical samples. At the end of the two years, we will demonstrate the production of novel compositions of conductive nanomaterials/inks and their screen-printing on flexible substrates, enabling the conversion of electrodes to electrochemical nano-biosensors in one single step. The project will also lead to the development of a new microfluidic platform with a developed library of characterized capillary microfluidic components, and once combined, can automate complex protocols of electrochemical biosensing into one single chip. Our proposed CAMEN-based bioassays would 1) be automated and quantitative sample-to-result tests, 2) be modular and easily adaptable for making new assays, 3) have multiplexing capability for detecting various types of biomarkers simultaneously in one single kit, 4) be rapid (<20 min) and low-cost (<$15-20), and 5) be compatible with digital health monitoring due to the wireless signal transfer to Web-App and Cloud-systems, aligned with the needs of emerging digital health platforms in Canada. This project will lead to economic benefits to Canada by creating demands for Canada's products and IPs related to micro- and nano-technologies, diagnostic platforms, and medical devices.